Proproteína convertasa subtilisina-kexina tipo 9 (IPCSK9) y riesgo residual

Mitigating residual risk is one of the primary objectives of cardiovascular medicine, achieved through a holistic and transdisciplinary approach to managing cardiovascular risk factors. It involves the use of increasingly potent therapies that can positively impact clinical outcomes while ensuring patient safety. Consequently, the use of PCSK9-inhibiting medications has become a straightforward and highly recommended strategy in clinical practice guidelines for lipid management and lipid-related risk factor intervention. These medications have effectively been proven to reduce recurrent cardiovascular events and have a legacy effect on lipid levels, and are considered safe in achieving extremely low LDL-c levels.